Theriva Financial Statements From 2010 to 2026

TOVX Stock  USD 0.19  0.02  9.52%   
Theriva Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Theriva Biologics' valuation are provided below:
Market Capitalization
6.7 M
Earnings Share
2.06
We have found one hundred twenty available fundamental trend indicators for Theriva Biologics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Theriva Biologics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 2.6 M in 2026. Enterprise Value is likely to rise to about (8.4 M) in 2026
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 96.1 K, Total Revenue of 0.0 or Other Operating Expenses of 31.8 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.14. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Build AI portfolio with Theriva Stock
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Theriva Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets42.7 M40.7 M29.5 M
Slightly volatile
Total Current Liabilities9.2 M8.7 M6.5 M
Slightly volatile
Accounts Payable1.1 M987.9 K1.2 M
Very volatile
Cash12.9 M13.4 M19.3 M
Slightly volatile
Non Current Assets Total23 M21.9 M7.4 M
Slightly volatile
Cash And Short Term Investments13 M13.4 M19.3 M
Slightly volatile
Liabilities And Stockholders Equity42.7 M40.7 M29.5 M
Slightly volatile
Other Stockholder Equity428.9 M408.5 M224 M
Slightly volatile
Total Liabilities19.7 M18.7 M10.3 M
Slightly volatile
Total Current Assets14.5 M18.7 M21.9 M
Slightly volatile
Other Current Liabilities7.4 MM5.2 M
Pretty Stable
Property Plant And Equipment Net1.9 M1.8 M897.1 K
Slightly volatile
Short and Long Term Debt Total1.8 M1.4 MM
Slightly volatile
Short Term Debt512.3 K540 K313.4 K
Slightly volatile
Net ReceivablesM3.8 M912.4 K
Slightly volatile
Non Current Liabilities Total10.5 M10 M3.9 M
Slightly volatile
Short Term Investments338.7 K294.7 K337.5 K
Slightly volatile
Intangible Assets21 M20 M18.1 M
Slightly volatile
Common Stock2.6 K2.7 K54.8 K
Slightly volatile
Common Stock Shares Outstanding1.1 M1.6 M1.4 M
Slightly volatile
Other Liabilities10.7 M10.2 M4.5 M
Slightly volatile
Capital Stock2.6 K2.7 K11.8 M
Slightly volatile
Net Working Capital9.5 M10 M23.8 M
Pretty Stable
Property Plant Equipment1.1 M1.8 M921.5 K
Slightly volatile
Capital Lease Obligations1.4 M1.6 M997.4 K
Slightly volatile
Property Plant And Equipment Gross2.3 M2.8 M1.9 M
Slightly volatile
Long Term Debt126.7 K82.8 K196.3 K
Slightly volatile
Deferred Long Term Liabilities15.3 M17.2 M18.8 M
Slightly volatile
Short and Long Term Debt66.4 K70.2 K58.9 K
Slightly volatile
Non Current Liabilities Other5.5 M6.3 MM
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.8 M
Slightly volatile

Theriva Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses31.8 M30.3 M20.9 M
Slightly volatile
Cost Of Revenue186.8 K157.6 K149.8 K
Slightly volatile
Total Operating Expenses31.8 M30.3 M20.9 M
Slightly volatile
Research Development9.7 M13.8 M12.9 M
Very volatile
Interest Expense519.2 K494.5 K196.5 K
Slightly volatile
Selling General Administrative6.7 M8.5 M5.6 M
Slightly volatile
Selling And Marketing Expenses983.1 K561.6 K1.2 M
Slightly volatile
Net Interest Income479.4 K801.5 K286.4 K
Slightly volatile
Interest Income479.4 K801.5 K286.4 K
Slightly volatile
Reconciled Depreciation130.6 K123.3 K210.2 K
Slightly volatile

Theriva Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow28.1 M26.8 M20.4 M
Slightly volatile
End Period Cash Flow12.9 M13.5 M19.3 M
Slightly volatile
Stock Based Compensation1.2 M603.9 K1.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio241254381
Slightly volatile
Days Sales Outstanding82.9887.35115
Slightly volatile
Average Payables761.9 K383.2 K400.9 K
Pretty Stable
Stock Based Compensation To Revenue0.230.240.3844
Slightly volatile
EV To Sales188198204
Slightly volatile
Payables Turnover0.350.30.1925
Slightly volatile
Research And Ddevelopement To Revenue0.430.451.0982
Slightly volatile
Capex To Revenue0.00340.00360.0155
Slightly volatile
Cash Per Share9.419.996.4633
Slightly volatile
Days Payables Outstanding1.5 K1.6 KK
Slightly volatile
Income Quality0.670.590.8608
Pretty Stable
Intangibles To Total Assets0.460.440.3537
Slightly volatile
Net Debt To EBITDA0.660.471.0726
Pretty Stable
Current Ratio1.841.937.6528
Slightly volatile
Receivables Turnover2.314.324.3772
Pretty Stable
Debt To Equity0.07760.07390.0567
Very volatile
Capex Per Share8.0E-49.0E-40.653
Slightly volatile
Average Receivables28.3 K38.7 K41 K
Very volatile
Revenue Per Share46.7444.5146.1998
Slightly volatile
Interest Debt Per Share1.271.341.8874
Slightly volatile
Debt To Assets0.04840.05090.0442
Slightly volatile
Operating Cycle82.9887.35115
Slightly volatile
Days Of Payables Outstanding1.5 K1.6 KK
Slightly volatile
Ebt Per Ebit0.690.880.9332
Slightly volatile
Total Debt To Capitalization0.07170.06830.0533
Very volatile
Debt Equity Ratio0.07760.07390.0567
Very volatile
Quick Ratio1.841.937.6495
Slightly volatile
Net Income Per E B T1.341.061.0138
Pretty Stable
Cash Ratio1.311.386.8148
Slightly volatile
Days Of Sales Outstanding82.9887.35115
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0212
Slightly volatile
Fixed Asset Turnover5.855.575.9173
Slightly volatile
Debt Ratio0.04840.05090.0442
Slightly volatile
Price Sales Ratio241254381
Slightly volatile
Asset Turnover0.730.690.7207
Slightly volatile
Gross Profit Margin0.630.770.8312
Slightly volatile

Theriva Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 M2.7 M973.2 M
Slightly volatile

Theriva Fundamental Market Drivers

Theriva Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue157.6 K186.8 K
Stock Based Compensation To Revenue 0.24  0.23 
Research And Ddevelopement To Revenue 0.45  0.43 
Revenue Per Share 44.51  46.74 
Ebit Per Revenue(0.58)(0.60)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.